BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: MacCamy K, Hu D. Dexmedetomidine for Treatment of Delayed Peak Symptoms of Cannabis Withdrawal Syndrome: A Case Report. Hosp Pharm 2021;56:462-5. [PMID: 34720146 DOI: 10.1177/0018578720919025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Baumgartner K, Groff V, Yaeger LH, Fuller BM. The use of dexmedetomidine in the emergency department: A systematic review. Acad Emerg Med 2023;30:196-208. [PMID: 36448276 DOI: 10.1111/acem.14636] [Reference Citation Analysis]
2 Baumgartner K, Doering And M, Mullins ME; Toxicology Investigators Consortium. Dexmedetomidine in the treatment of toxicologic conditions: a systematic review and review of the toxicology investigators consortium database. Clin Toxicol (Phila) 2022;60:1356-75. [PMID: 36346349 DOI: 10.1080/15563650.2022.2138761] [Reference Citation Analysis]
3 . Dexmedetomidine. Reactions Weekly 2022;1899:164-164. [DOI: 10.1007/s40278-022-12138-2] [Reference Citation Analysis]
4 Laudanski K, Wain J. Considerations for Cannabinoids in Perioperative Care by Anesthesiologists. J Clin Med 2022;11:558. [PMID: 35160010 DOI: 10.3390/jcm11030558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]